ACS Medicinal Chemistry Letters
Notes
The authors declare the following competing financial
interest(s): we have been requested to add the following
disclosure:The authors are all employees of GlaxoSmithKline
and have a financial interest in GlaxoSmithKline.
Letter
(18) O’Brien, D. E.; Robins, R. K. Xanthine Oxidase Inhibitors. U.S.
Patent 3,907,799, September 23, 1975.
(19) Guzi, T. J.; Paruch, K.; Dwyer, M. P. Novel Pyrazolopyrimidines
as Cyclin Dependent Kinase Inhibitors. U.S. 2006/0041131, February
23, 2006.
(20) Hunt, P.; Porter, D.; Press, N. J.; Spanka, C.; Watson, S. J. 5-
Sulfanylmethyl-pyrazolo[1,5a]pyrimidin-7-ol Derivatives as CXCR2
Antagonists. WO 2008/062026, May 29, 2008.
REFERENCES
■
(21) Lin, L. S.; Hagmann, W. K.; Kumar, S.; Yin, W. Substituted
(1) Fruman, D. A.; Meyers, R. E.; Cantley, L. C. Phosphoinositide
Kinases. Annu. Rev. Biochem. 1998, 67, 481−507.
(2) Rameh, L. E.; Cantley, L. C. The Role of Phosphoinositide 3-
Kinase Lipid Products in Cell Function. J. Biol. Chem. 1999, 274,
8347−8350.
Amides. WO 2004/058145, July 15, 2004.
(22) Gray, A.; Olsson, H.; Batty, I. H.; Priganica, L.; Downes, C. P.
Nonradioactive methods for the assay of phosphoinositide 3-kinases
and phosphoinositide phosphatases and selective detection of signaling
lipids in cell and tissue extracts. Anal. Biochem. 2003, 313, 234−245.
(23) Ikawa, T.; Barder, T. E.; Biscoe, M. R.; Buchwald, S. L. Pd-
Catalyzed Amidations of Aryl Chlorides Using Monodentate Biaryl
Phosphine Ligands: A Kinetic, Computational and Synthetic
Investigation. J. Am. Chem. Soc. 2007, 129, 13001−13007.
(24) Protein binding was estimated by HPLC analysis using
commercially available immobilized human serum albumin or α-acid
glycoprotein columns eluted with a gradient of 50 mM NH4OAc, pH
7.4, and isopropanol.
(25) Cells were plated and grown overnight in normal serum-
containing medium (10% FBS) as described previously.17 The
medium was then exchanged for serum-free medium, and the cells
were incubated with or without compound for 30 min and assayed as
usual.
(3) Aoki, M.; Schetter, C.; Himly, M.; Batista, O.; Chang, H. W.;
Vogt, P. K. The Catalytic Subunit of Phosphoinositide 3-Kinase:
Requirements for Oncogenicity. J. Biol. Chem. 2000, 275, 6267−6275.
(4) Kang, S.; Bader, A. G.; Vogt, P. K. Phosphatidylinositol 3-kinase
mutations identified in human cancer are oncogenic. Proc. Natl. Acad.
Sci. U.S.A. 2005, 102, 802−807.
(5) Vogt, P. K.; Kang, S.; Elsliger, M.-A.; Gymnopoulos, M. Cancer-
specific mutations in phosphatidylinositol 3-kinase. Trends Biochem.
Sci. 2007, 32, 342−349.
(6) Engelman, J. A. Targeting PI3K signalling in cancer:
Opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9,
550−562.
(7) Nuss, J. M.; Tsuhako, A. L.; Anand, N. K. Emerging Therapies
Based on Inhibitors of Phosphatidyl-Inositol 3-Kinases. Annu. Rep.
Med. Chem. 2009, 44, 339−355.
(8) Holand, K.; Salm, F.; Arcaro, A. The Phosphoinositide 3-Kinase
̈
Signalling Pathway as a Therapeutic Target in Grade IV Brain Tumors.
Curr. Cancer Drug Targets 2011, 11, 894−918.
(9) Samuels, Y.; Ericson, K. Oncogenic PI3K and its role in cancer.
Curr. Opin. Oncol. 2006, 18, 77−82.
(10) Zhang, J.; Roberts, T. M.; Shivdasani, R. A. Targeting PI3K
Signalling as a Therapeutic Approach for Colorectal Cancer.
Gastroenterology 2011, 141, 50−61.
(11) Jia, S.; Liu, Z.; Zhang, S.; Liu, P.; Zhang, L.; Lee, S. H.; Zhang, J.;
Signoretti, S.; Loda, M.; Roberts, T. M.; Zhao, J. J. Essential roles of
PI(3)K-p110β in cell growth, metabolism and tumorigenesis. Nature
2008, 454, 776−780.
(12) Wee, S.; Wiederschain, D.; Maira, S.-M.; Loo, A.; Miller, C.;
deBeaumont, R.; Stegmeier, F.; Yao, Y.-M.; Lengauer, C. PTEN-
deficient cancers depend on PI3KCB. Proc. Natl. Acad. Sci. U.S.A.
2008, 105, 13057−13062.
(13) Lee, S. H.; Poulogiannis, G.; Pyne, S.; Jia, S.; Zou, L.; Signoretti,
S.; Loda, M.; Cantley, L. C.; Roberts, T. M. A constitutively activated
form of the p110β isoform of PI3-kinase induces prostatic intra-
epithelial neoplasia in mice. Proc. Natl. Acad. Sci. U.S.A. 2010, 107,
11002−11007.
(26) Lin, H.; Schulz, M. J.; Xie, R.; Luengo, J. I.; Squire, M. D.;
Tedesco, R.; Qu, J.; Erhard, K.; Mack, J. F.; Raha, K.; Plant, R.;
Rominger, C. M.; Ariazi, J. L.; Sherk, C. S.; Schaber, M. D.; McSurdy-
Freed, J.; Spengler, M. D.; Davis, C. B.; Hardwicke, M. A.; Rivero, R.
A. Rational design, synthesis and SAR of a novel thiazolopyrimidinone
series of selective PI3Kβinhibitors. ACS Med. Chem. Lett. 2012, 3,
524−529.
(27) All animal studies were conducted after review by the GSK
Institutional Animal Care and Use Committee and were in accordance
with the GSK Policy on the Care, Welfare and Treatment of
Laboratory Animals.
(28) Smith, D. A.; Di, L.; Kerns, E. H. The effect of plasma protein
binding on in vivo efficacy: misconceptions in drug discovery. Nature
Rev. Drug Discovery 2010, 9, 929−939.
(14) Hill, K. M.; Kalifa, S.; Das, J. R.; Bhatti, T.; Gay, M.; Williams,
D.; Taliferro-Smith, L.; De Marzo, A. M. The Role of PI3-Kinase
p110β in AKT Signalling, Cell Survival, and Proliferation in Human
Prostate Cancer Cells. Prostate 2010, 70, 755−764.
(15) Dbouk, H. A.; Backer, J. M. A beta version of life: p110β takes
center stage. Oncotarget 2010, 1, 729−733.
(16) Lin, H.; Erhard, K.; Hardwicke, M. A.; Luengo, J. I.; Mack, J. F.;
McSurdy-Freed, J.; Plant, R.; Raha, K.; Rominger, C. M.; Sanchez, R.;
Schaber, M. D.; Schulz, M.; Spengler, M. D.; Tedesco, R.; Xie, R.;
Zeng, J. J.; Rivero, R. A. Synthesis and structure-activity relationships
of imidazo[1,2a]pyrimidin-5(1H)-ones as a novel series of beta
isoform selective phosphatidylinositol-3-kinase inhibitors. Bioorg. Med.
Chem. Lett. 2012, 22, 2230−2234.
(17) Sanchez, R.; Erhard, K.; Hardwicke, M. A.; Lin, H.; McSurdy-
Freed, J.; Plant, R.; Raha, K.; Rominger, C. M.; Schaber, M. D.;
Spengler, M. D.; Moore, M. L.; Yu, H.; Luengo, J. I.; Tedesco, R.;
Rivero, R. A. Synthesis and structure activity relationships of 1,2,4-
triazolo[1,5a]pyrimidin-7(3H)-ones as a novel series of potent beta
isoform selective phosphatidylinositol 3-kinase inhibitors. Bioorg. Med.
Chem. Lett. 2012, 22, 3198−3202.
E
dx.doi.org/10.1021/ml300330m | ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX